Le rhinovirus (RV) est connu pour être l'étiologie de plus de la moitié des rhumes bénins. Ces virus ont également été associés à des pathologies respiratoires beaucoup plus graves (asthme, bronchopneumopathie chronique obstructive (BPCO) et mucoviscidose). Le développement d'inhibiteurs de décapsidation du virus, appelés agents « capsid-binders », est ainsi devenu une priorité pour de nombreux laboratoires de recherche. Dans ce contexte, une classe d’inhibiteurs se liant au sein de la poche hydrophobe de la protéine capsidaire VP1 a été développée par notre équipe au travers d’une stratégie radicalaire médiée par le TDAE (Tétrakis(DiméthylAmino)Ethylène). Dans le but de poursuivre les investigations sur le hit LPCRW_0005, un travail de pharmacochimie a été entrepris selon deux approches. Dans un premier temps, une optimisation de la taille du LPCRW_0005 a été envisagée par un allongement du squelette chimique. La conception de ces molécules a été guidée par l’utilisation de modélisation moléculaire via la réalisation de docking rigide ligand/protéine. La synthèse de nombreux composés et leur évaluation in vitro, ont permis de mieux apprécier le potentiel biologique de ce type de dérivés. L’identification de la configuration active du centre stéréogène porté par le linker alcool a été rendue possible par la séparation énantiosélective de certains inhibiteurs suivie d’une caractérisation basée sur un protocole de Mosher. Dans un second temps, une étude comparative des séquences primaires protéiques, nous ont conduits à concevoir de nouveaux composés afin de développer des « capsid-binders » à plus large spectre d'action. / Rhinovirus (RV), virus of Picornaviridae family, is known to be the aetiology of more than half of the common cold. Through advances in molecular biology, the rhinoviruses have been associated with much more serious respiratory pathologies (asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis). So, the development of viral attachment and/or uncoating inhibitors named « capsid-binders » molecules has become a priority for many research laboratories. In this context, a class of inhibitors binding into a hydrophobic pocket of the VP1 capsid protein has been identified by our team through a TDAE strategy. In order to follow the investigations on the LPCRW_0005 hit, a pharmacochemistry work was begun according to two approaches. Initially, an optimisation of the LPCRW_0005 size was envisaged by an extension of the scaffold via various pallado-catalyzed cross-coupling reactions. The design of these molecules was guided by the use of molecular modeling via a rigid ligand/protein docking. The synthesis of many compounds and their in vitro biological evaluation on HeLa cells infected with the rhinovirus 14 (RV-B14), refined our knowledge about the biological potential of such a scaffold. The enantioselective separation of some inhibitors followed by a Mosher’s protocol allowed us to identify the active configuration of the alcohol linker. Finally, a comparative study of protein primary sequences as well as drug design, led us to design and develop more potent broad-spectrum capsid-binders.

Like all other viruses, a successful egress of functional particles from infected cells is a prerequisite for foamy virus (FV) spread within the host. The budding process of FVs involves steps, which are shared by other retroviruses, such as interaction of the capsid protein with components of cellular vacuolar protein sorting (Vps) machinery via late domains identified in some FV capsid proteins. Additionally, there are features of the FV budding strategy quite unique to the spumaretroviruses. This includes secretion of non-infectious subviral particles and a strict dependence on capsid-glycoprotein interaction for release of infectious virions from the cells. Virus-like particle release is not possible since FV capsid proteins lack a membrane-targeting signal. It is noteworthy that in experimental systems, the important capsid-glycoprotein interaction could be bypassed by fusing heterologous membrane-targeting signals to the capsid protein, thus enabling glycoprotein-independent egress. Aside from that, other systems have been developed to enable envelopment of FV capsids by heterologous Env proteins. In this review article, we will summarize the current knowledge on FV budding, the viral components and their domains involved as well as alternative and artificial ways to promote budding of FV particle structures, a feature important for alteration of target tissue tropism of FV-based gene transfer systems.

Innerhalb der Retroviren unterscheiden sich die Foamyviren (FV) bezüglich ihrer Proteinexpression, der Partikelmorphogenese und ihres Reproduktionszyklus deutlich von den Orthoretroviren. Im Rahmen dieser Arbeit wurden zwei exklusive Merkmale der Foamyviren, die ungewöhnliche Struktur des Gag-Proteins und die Gag unabhängige Pol-Expression, in ihrer Auswirkung auf Morphogenese und Zusammensetzung foamyviraler Partikel untersucht. Für die Morphogenese infektiöser Partikel sind sehr unterschiedliche Mengen der Genprodukte eines Retrovirus nötig. Im Gegensatz zu den Orthoretroviren wird bei Foamyviren das Produkt des pro/pol-ORFs von einer eigenen, gespleißten mRNA translatiert. Der Gag/Pro/Pol-Gehalt in den Viruspartikeln kann folglich nicht wie bei Orthoretroviren über eine gekoppelte Translation und Inkorporation von Gag- und Gag/Pro/Pol-Fusionsproteinen reguliert werden. In dieser Arbeit wurde der Frage nach dem molekularem Verhältnis von Gag- und Pro/Pol-Proteinen in foamyviralen Partikeln nachgegangen. In den isolierten PFV Partikeln war der relative Gehalt an dem Gag-Prozessierungsprodukt p68 viermal höher als der Gehalt an dem Gag-Vorläuferprotein p71. Das Gag-Prozessierungsprodukt p68 bildet somit das Hauptstrukturelement der PFV Kapside. Weiterhin ergab sich ein Verhältnis von 16 Gag-Molekülen zu einem p85PR/RT-Molekül sowie 10 Gag-Molekülen pro p40IN-Molekül. Damit entsprach die Gag/Pol-Zusammensetzung von PFV Partikeln den stöchiometrischen Verhältnissen in orthoretroviralen Partikeln von 10 - 20 Gag-Molekülen pro Pol-Molekül. Dieses Ergebnis ist in Hinsicht auf die unterschiedlichen Synthesestrategien von Gag und Pol bei Orthoretro- und Foamyviren bemerkenswert. Basierend auf diesen Ergebnissen stellt sich für weiterführende Untersuchungen nun die Frage nach der Regulation der Gag- und Pol-Synthese bei Foamyviren. Bei Orthoretroviren setzt sich in einem Prozess der Selbstorganisation das Strukturprotein Gag autonom zu virusähnlichen Partikeln zusammen, die auch in Abwesenheit weiterer viraler Komponenten aus der Wirtszelle freigesetzt werden. Foamyviren dagegen benötigen für die Freisetzung ihrer Viruspartikel neben dem Strukturprotein obligat die Koexpression ihres Glykoproteins. Im zweiten Teil dieser Arbeit wurden funktionelle Abschnitte im PFV Gag-Protein eingegrenzt und charakterisiert, die eine Rolle bei der Bildung und Freisetzung der viralen Partikel spielen. Eine schrittweise Deletion des PFV Gag-Proteins vom C-Terminus her zeigte, dass die N-terminalen 300 As von PFV Gag ausreichend für die Freisetzung von partikulärem viralem Proteinmaterial sind. Die Analyse weiterer Deletionsmutanten innerhalb des N-Terminus des PFV Gag-Proteins belegte, dass die As 6 - 200 für die Bildung viraler Kapside entbehrlich sind, aber für die Interaktion mit dem viralen Glykoprotein und für eine Freisetzung der viralen Partikel aus der Wirtszelle essentiell sind. Die Substitution einzelner konservierter Aminosäuren durch Alanin zwischen As 40 - 60 blockierte die Partikelmorphogenese. Die Aminosäureabfolge dieses Proteinabschnittes zeigte eine große Ähnlichkeit mit einem zellulären Transportsignal, dass in den Gag-Proteinen von Retroviren des Typ-D-Morphogeneseweges entdeckt worden ist. Eine parallele Mutationsanalyse des FFV Gag-Proteins ließ vermuten, dass dieses Motiv wohl universell in allen FV Gag-Proteinen vorhanden ist. Weiterhin konnten Aminosäureabschnitte am unmittelbaren N-Terminus des PFV Gag-Proteins sowie zwischen As 130 - 200 eingegrenzt werden, die essentiell für die Struktur des Proteins sind und eventuell eine wichtige Funktion bei der Partikelmorphogenese erfüllen. Weitere Untersuchungen und insbesondere eine Strukturaufklärung des PFV Gag-Proteins sind nötig, um die genaue Funktion der einzelnen Proteinabschnitte zu charakterisieren.

Human norovirus (HuNoV) is the leading cause of gastroenteritis worldwide. Despite the significant disease and economic burden, currently there are no licensed vaccines or antivirals. The understanding of norovirus biology has been hampered by the inability to cultivate HuNoV in cell culture. To establish a tissue culture system, infectious HuNoVs were purified from clinical stool samples. HuNoV replication was tested in different cell types. The B-cell and intestinal organoids culture systems were validated. In addition, using organoids culture a DNA-based reverse genetic system was shown to recover infectious HuNoV. Due to the challenges associated with cultivating HuNoV, murine norovirus (MNV) was used as a surrogate system to understand the role of eIF4E phosphorylation in norovirus pathogenesis, and VP1-RdRp interaction in regulating viral genome replication. MNV infection results in the phosphorylation of the translation initiation factor eIF4E, re-programming host-cell translation during infection. Inhibiting eIF4E phosphorylation reduces MNV replication in cell culture suggesting a role in viral replication. A mouse model with eIF4E S209A, a phosphor-ablative mutation, was established to understand the role of eIF4E phosphorylation in MNV pathogenesis. In vitro and in vivo characterisations demonstrated that eIF4E phosphorylation may have multiple roles in norovirus-host interactions, but overall has little impact on MNV pathogenesis. The shell domain (SD) of norovirus major capsid protein VP1 interacts with viral RNA-dependent RNA polymerase (RdRp) in a genogroup-specific manner to enhance de novo initiation of RdRp, and to promote negative-strand RNA synthesis. To understand how VP1 regulates norovirus genome replication, chimeric MNVs with genogroup-specific residues mutagenised were characterised in vitro and in vivo. A single amino acid mutation was shown to destabilise viral capsid. SDs with reduced VP1-RdRp interaction showed less capacity to stimulate RdRp, resulting in delayed virus replication. In vivo, the replication of an MNV-3 with homologous mutations was abolished, highlighting the crucial role of this interaction.

Luk, Chun Shui. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2009. / Includes bibliographical references (leaves 174-189). / Abstract also in Chinese. / Declaration --- p.I / Acknowledgements --- p.II / Funding Support --- p.IV / Abstract of thesis entitled --- p.V / 論文摘要 --- p.VII / Abbreviations --- p.IX / Table of Contents --- p.XIII / List of Figures --- p.XVIII / List of Tables --- p.XX / List of Appendix --- p.XXI / Chapter Chapter One - --- Literature Review --- p.1 / Chapter 1.1 --- History of Knowledge on Human Papillomavirus --- p.1 / Chapter 1.2 --- Virology of Human Papillomavirus --- p.2 / Chapter 1.2.1 --- Taxonomic Classification of Human Papillomavirus --- p.2 / Chapter 1.2.2 --- Morphology of Human Papillomavirus --- p.3 / Chapter 1.2.3 --- The Viral Genome --- p.3 / Chapter 1.2.4 --- The Viral Gene Products --- p.5 / Chapter 1.2.4.1 --- E1 and E2 Proteins --- p.5 / Chapter 1.2.4.2 --- E4 Protein --- p.6 / Chapter 1.2.4.3 --- "E5，E6, E7 Proteins" --- p.7 / Chapter 1.2.4.4 --- L1 and L2 Proteins --- p.8 / Chapter 1.3 --- Evolution of Human Papillomavirus --- p.9 / Chapter 1.3.1 --- Rates of Evolution --- p.11 / Chapter 1.3.2 --- Co-evolution Between Human Papillomavirus and Human --- p.11 / Chapter 1.4 --- Human Papillomavirus Infection and Disease --- p.13 / Chapter 1.4.1 --- Human Papillomavirus and Cervical Cancer --- p.13 / Chapter 1.4.1.1 --- Disease Burden of Cervical Cancer --- p.13 / Chapter 1.4.1.2 --- Epidemiology of Cervical Cancer --- p.14 / Chapter 1.4.1.3 --- Distribution of HPV types in Cervical Precancerous Lesions --- p.14 / Chapter 1.4.2 --- Human Papillomavirus and Non-cervical Diseases --- p.15 / Chapter 1.5 --- Human Papillomavirus Type 58 --- p.15 / Chapter 1.5.1 --- Biology of Human Papillomavirus Type 58 --- p.15 / Chapter 1.5.2 --- Epidemiology of Human Papillomavirus Type 58 Infections --- p.16 / Chapter Chapter Two - --- Background and Objectives of Study --- p.17 / Chapter 2.1 --- Background of study --- p.17 / Chapter 2.1.1 --- The Need for Research on HPV58 --- p.17 / Chapter 2.1.2 --- Intratypic Classification System for HPV --- p.17 / Chapter 2.2 --- Implication and Impact of Study --- p.19 / Chapter 2.2.1 --- Implication on HPV Virology --- p.19 / Chapter 2.2.2 --- HPV58 Classification --- p.19 / Chapter 2.2.3 --- Improvement on in the Detection of HPV58 --- p.20 / Chapter 2.2.4 --- Implication on Vaccine Development --- p.20 / Chapter 2.3 --- Objectives of Study --- p.21 / Chapter 2.3.1 --- To Generate a Database for Intratypic Variation of Different Gene Regions of HPV58 --- p.21 / Chapter 2.3.2 --- To Study the Variability of Seven Gene Regions of HPV58 --- p.21 / Chapter 2.3.3 --- To Study the Geographical Distribution of HPV58 Variants --- p.22 / Chapter 2.3.4 --- To Study the Phylogeny of HPV58 --- p.22 / Chapter 2.3.5 --- To Develop an Intratypic Classification System for HPV58 --- p.22 / Chapter 2.3.6 --- To Predict the Effectiveness of Commonly Used Primers on the Detection of HPV58 --- p.22 / Chapter Chapter Three - --- Materials and Methods --- p.24 / Chapter 3.1 --- Overall Study Design --- p.24 / Chapter 3.2 --- Study Population --- p.25 / Chapter 3.3 --- Sample Processing and Storage --- p.25 / Chapter 3.4 --- Primer Design --- p.26 / Chapter 3.5 --- Specimen Quality Assessment and Sample Selection --- p.30 / Chapter 3.6 --- Amplification of Gene Region --- p.30 / Chapter 3.7 --- Agarose Gel Electrophoresis --- p.34 / Chapter 3.8 --- Sequencing Reaction --- p.34 / Chapter 3.8.1 --- Purification of PCR Product --- p.34 / Chapter 3.8.2 --- Sequencing Reaction --- p.35 / Chapter 3.8.3 --- Purification of Fluorescence-labelled Product --- p.35 / Chapter 3.8.4 --- Sequence Identification --- p.35 / Chapter 3.9 --- Sequence Analysis --- p.36 / Chapter 3.9.1 --- Sequence Editing --- p.36 / Chapter 3.9.2 --- Criteria for Confirming the identity of HPV58 --- p.36 / Chapter 3.9.3 --- Identification of Variants --- p.38 / Chapter 3.9.4 --- Identification of Conserved and Variable Regions --- p.39 / Chapter 3.9.5 --- Phylogenetic Analysis --- p.40 / Chapter 3.9.5.1 --- Construction of Maximum Likelihood Tree --- p.40 / Chapter 3.9.5.2 --- Bootstrap Analysis --- p.41 / Chapter 3.9.5.3 --- Bayesian Phylogenetic Analysis --- p.42 / Chapter 3.9.5.4 --- Non-synonymous to Synonymous Substitution Rate Ratio (dN/dS) --- p.42 / Chapter 3.9.6 --- Evaluation of Performance of Commonly Used Primers --- p.43 / Chapter Chapter Four - --- Results --- p.44 / Chapter 4.1 --- Specimen Quality Assessment and HPV58 Confirmation --- p.44 / Chapter 4.2 --- HPV58 Genome Variability --- p.44 / Chapter 4.2.1 --- E6 Open Reading Frame --- p.45 / Chapter 4.2.2 --- E7 Open Reading Frame --- p.51 / Chapter 4.2.3 --- E2 Open Reading Frame --- p.56 / Chapter 4.2.4 --- E4 Open Reading Frame --- p.61 / Chapter 4.2.5 --- E5 Open Reading Frame --- p.66 / Chapter 4.2.6 --- L1 Open Reading Frame --- p.71 / Chapter 4.2.7 --- Long Control Region --- p.88 / Chapter 4.2.8 --- Whole HPV genome --- p.94 / Chapter 4.3 --- Evaluation of Commonly Used Primers --- p.99 / Chapter 4.3.1 --- PGMY09/11 Primers --- p.99 / Chapter 4.3.2 --- MY09/11 Primers --- p.99 / Chapter 4.3.3 --- GP5+/6+ Primers --- p.100 / Chapter 4.3.4 --- SPF Primers --- p.100 / Chapter 4.3.5 --- L1F/L1R Primers --- p.101 / Chapter Chapter Five - --- Discussion --- p.111 / Chapter 5.1 --- Overall Variation of HPV58 Genome --- p.111 / Chapter 5.2 --- Variability of Each Gene Region --- p.114 / Chapter 5.2.1 --- E6 Open Reading Frame --- p.115 / Chapter 5.2.2 --- E7 Open Reading Frame --- p.116 / Chapter 5.2.3 --- E2 Open Reading Frame --- p.117 / Chapter 5.2.4 --- E4 Open Reading Frame --- p.118 / Chapter 5.2.5 --- E5 Open Reading Frame --- p.119 / Chapter 5.2.6 --- L1 Open Reading Frame --- p.120 / Chapter 5.2.7 --- Long Control Region --- p.121 / Chapter 5.3 --- Phylogenetics of HPV58 --- p.122 / Chapter 5.3.1 --- Natural Selection Pressure --- p.122 / Chapter 5.3.2 --- HPV58 Lineage Using the L1 Gene --- p.124 / Chapter 5.3.3 --- Methods for Lineage Identification --- p.125 / Chapter 5.3.4 --- Geographical Distribution of the Four Lineages --- p.126 / Chapter 5.3.5 --- Recombination --- p.127 / Chapter 5.4 --- Evaluation of Commonly Used Primers --- p.128 / Chapter 5.5 --- Limitations of the Current Study --- p.129 / Chapter 5.6 --- Future Studies --- p.130 / Appendix --- p.133 / References --- p.174

Many T=3 plant and insect viruses use a molecular switch in form of order/disorder of a segment of the polypeptide chain to regulate the quasi-equivalent contacts. The structure of a mutant of the T=3 capsid of bacteriophage fr confirms that this virus and other members of the Leviviridae family lack a switch mechanism. The geometric principles underlying the construction of spherical virus capsid do not allow more than 60 protein monomers to from a capsid while maintaining an identical chemical environment. Most virus capsid, however, contain many more protein subunits. Quasi-equivalence explains how the capsid proteins can have slightly different interactions in the virus shell. Quasi-equivalence requires the capsids to be constructed from multiples of 60 subunits, where the T number denotes the multiplicity. The structure of the T=4 Nudaurelia capensis ω Virus shows a molecular switch in form of a C-terminal helix inserted in some contacts between protein dimers. This virus is very similar in structure to the T=3 nodaviruses. In the nodaviruses a five-membered helix bundle, formed by cleaved peptides around the five-fold axes on the inside of the shell, are suggested to aid in membrane translocation of the genomic RNA. In Nudaurelia capensis ω Virus the helix bundle is formed by 10 helices, of which 5 are still covalently attached to the capsid proteins. Bacteriophage HK97 has T=7 quasi-symmetry. A domain that is degraded during maturation and is not present in the structure of the mature virion controls the quasi-equivalence. During maturation covalent bonds are formed between the protein subunits, producing a set of interlocking covalently bound rings, resembling chainmail. Structural studies of complexes between the bacteriophage MS2 and variants of its translational operator are also included in this work. A dimer of the MS2 coat protein binds with sequence specificity to an operator in its genomic RNA, and causes translational repression. Structures of multiple RNA segments with altered sequence at some positions which are required for binding to the capsid protein, has been determined.

The flavivirus West Nile virus (WNV) encodes a single polyprotein that is processed into three structural and seven nonstructural proteins. Various WNV bicistronic replicons that direct cap-dependent translation of an N-terminal viral capsid or capsid/Renilla luciferase fusion protein as well as IRES-dependent translation of the nonstructural proteins were constructed. An original replicon consisting of the WNV 5' NCR, the 5' 198 nts of the capsid coding sequence, which included the 5' cyclization sequence (Cyc), and an EMCV IRES followed by the WNV nonstructural genes and 3' NCR was generated. Real time qRT-PCR analysis of intracellular levels of this replicon RNA showed a 4 fold increase by 96 hr after transfection of BHK cells. Increasing the distance between the 5' Cyc and IRES by insertion of a 5' IRES flanking sequence alone or together with a Renilla luciferase reporter did not increase RNA replication. Addition of only a reporter decreased RNA replication. The insertion of an extended capsid coding sequence also did not enhance RNA replication, but did enhance both cap- and IRES-dependent translation of replicon RNA, as indicated by immunofluorescence and Western blot analysis. These results suggest the presence of a translation enhancer in the 3' portion of the capsid coding region. Simian hemorrhagic fever virus (SHFV) is a member of the family Arteriviridae, order Nidovirales. SHFV is unique among Nidoviruses in having three instead of two papain-like cysteine protease (PCP) motifs designated alpha, beta, and gamma, within the N-terminal region of its ORF1a. Mutations of putative PCP cleavage sites showed that the most efficient cleavage was by PCP beta at its downstream cleavage site. A large deletion located between the two catalytic residues of PCP alpha was hypothesized to render this protease inactive. However, processing was observed at the cleavage site following PCP alpha. Mutational analyses confirmed that PCP alpha is an inactive protease, and that the cleavage sites downstream of PCP alpha are cleaved by PCP gamma. When the catalytic residues of PCP gamma were mutated, PCP beta was also able to back cleave at these sites. This "back" cleavage is a previously unreported activity for an arterivirus PCP.

Thesis (Ph.D.)--University of Alabama at Birmingham, 2009. / Title from PDF title page (viewed on July 15, 2010). Includes bibliographical references.

Made available in DSpace on 2014-06-11T19:27:20Z (GMT). No. of bitstreams: 0 Previous issue date: 2008-03-13Bitstream added on 2014-06-13T20:35:43Z : No. of bitstreams: 1 pereira_acb_me_sjrp.pdf: 828257 bytes, checksum: de1b44b38dfac1b95be8ef5a683e7543 (MD5) / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / O lenho estriado de rupestris ou cascudo (Rupestris stem pitting – RSP), um dos componentes do Complexo do lenho rugoso (“Rugose wood” - RW), é considerado uma das doenças de videira transmitidas por enxertia de grande relevância econômica para a viticultura. O Rupestris stem pitting associated virus – RSPaV foi associado com a doença do lenho estriado ou cascudo, sendo classificado como espécie do gênero Foveavirus, pertencente a família Flexiviridae. No presente trabalho, descrevem-se o sequenciamento do gene da proteína capsidial (CP) de um isolado brasileiro do RSPaV (RSPaV-SP), sua expressão em Escherichia coli, purificação da proteína capsidial recombinante e a produção de anti-soro policlonal em coelho. O sequenciamento do gene resultou em uma seqüência de 780 nucleotídeos e 259 aminoácidos deduzidos com massa molecular estimada de 28 kDa. A análise filogenética, entre a seqüência correspondente à CP do RSPaV-SP e outras variantes do mesmo vírus, evidenciou a formação de 4 grupos distintos, sendo o isolado brasileiro incluído no grupo da variante BS do RSPaV. A proteína capsidial recombinante foi purificada em coluna de afinidade e apresentou massa molecular estimada de 32kDa (4kDa da seqüência do vetor e 28kD da CP do RSPaV-SP). O anti-soro produzido apresentou-se específico na detecção da proteína capsidial recombinante purificada por “Western-blot”, sem reação com proteína heteróloga a partir da diluição 1:4000. Nesta diluição, o anti-soro foi efetivo na detecção do vírus em extratos de plantas infectadas, sendo que nenhuma reação foi observada com extratos de plantas sadias. Considerando-se que este vírus apresenta variações de concentração na planta durante as estações do ano, e que, os testes sorológicos foram realizados durante a estação de baixa concentração do vírus, os resultados... / Rupestris stem pitting (RSP), a component of the rugose wood (RW) complex, is one of the most graft-transmissible grapevine virus diseases with great economic importance for viticulture . Rupestris stem pitting-associated virus (RSPaV), genus Foveavirus within the family Flexiviridae, has been associated with this disease. This work reports the sequencing of the coat protein (CP) gene of a brazilian an isolate of RSPaV (RSPaV-SP), its expression in Escherichia coli, purification of the recombinant coat protein and production of a polyclonal antiserum in rabbit. CP gene was found to be 780nt long, with a 256 deduced amino acid sequence encoding a predicted protein of 28 kDa. In filogenetic analysis, with RSPaV-SP and other variants of the virus, four groups were found and the sequence of RSPaV-SP showed the highest identity with the variant RSPaV-BS. The recombinant coat protein was purified by affinity chromatography and showed a molecular weight of 32kDa (4 kDa from a small vector sequence plus 28 kDa for the CP of RSPaV-SP). The antiserum proved specific for detection of the recombinant protein by Western Blot, and did not react with heterologous proteins starting at a dilution of 1:4000. At this dilution, the antiserum was effective in the virus detection of leaf extracts of infected plants and no reaction was observed with extracts from healthy grapevines. Considering that the virus is found at low concentrations in the plants during the seasons of the year, the results obtained so far were highly satisfactory for RSPaV detection. Serological methods have advantages over the biological indexing method, since they are cheaper and can be used in large-scale tests such as ELISA. Experiments using the ELISA technique were not successful. Purification of the native recombinant protein would be an alternative more efective to detect the virus using these technique.

Dans le cas d'une infection chronique par le virus de l'hépatite B (HBV), les traitements actuels (IFN et analogues de nucléos(t)ides) ne permettent pas d'éradiquer l'infection du fait de la persistance de l'ADNccc et des phénomènes de résistance observés chez les patients. S'agissant des traitements par l'IFN, 70 % des patients porteurs chroniques sont non-répondeurs. En effet, le virus HBV aurait développé des stratégies immunosuppressives pour établir une infection persistante. La compréhension des mécanismes impliqués dans cette viro-immunosuppression devient ainsi un enjeu majeur dans la mise en place de nouvelles stratégies antivirales. Les objectifs de ma thèse ont consisté en l'étude des relations précoces entre HBV et les hépatocytes. Nous avons pu mettre en évidence que cette absence d'activation du système immunitaire était le résultat, non pas d'une « invisibilité » du virus, mais d'une inhibition active des réponses IFN de type I/III et proinflammatoires, précocement établie par le virus HBV pour établir une infection persistante. De façon intéressante, nous avons pu démontrer que la protéine HBc était capable d'inhiber spécifiquement l'activation des voies IFN via son interaction avec les promoteurs des gènes de l'immunité innée et l'installation de marques épigénétiques (H3K9me2/3) répressives sur ces gènes par recrutement d'histone méthyl-transférases. Ces résultats prônent l'utilisation de stratégies antivirales utilisant des anticapsides dégradant et/ou prévenant la localisation nucléaire de la protéine HBc, restaurant ainsi le potentiel immunitaire des hépatocytes, pouvant dès lors être exacerbé par des agonistes de PRRs / Current treatments against Hepatitis B virus (HBV) chronic infection (IFNs and nucleos(t)ide analogues) are inefficient due to the persistence of cccDNA and emergence of viral resistance observed in infected patients. So far, up to 70 % of these patients are non responders to IFN treatments and it seems that the virus itself is able to counteract actively the host innate immune responses to establish a persistent infection. Therefore, the understanding of molecular mechanisms involved in this immunosuppression is crucial to design new immunotherapeutic strategies. In this context, the aim of my thesis was to investigate the early interactions between HBV and the hepatocyte antiviral responses. We have determined that HBV is not only a weak inducer of the host immune response, but is also able to inhibit very early and actively type I/III IFNs and proinflammatory pathways to persist in the hepatocytes. Furthermore, we have identified HBc protein as the major determinant involved specifically in the inhibition of IFN responses by counteracting host innate immune gene activations leading to repressive epigenetic marks such as H3K9/K27me3, or the recruitment of histone methyl transferase enzymes to the host IFN gene promoters. These results highlight new immunotherapeutic strategies and proposed the use of anticapsids components to degrade or block the nuclear localization of HBc proteins in order to restore a potent immune response in the hepatocytes. These anticapsid treatments may be also combined to PRRs agonists in order to improve the host antiviral state and HBV replication control